From the Guidelines
Trelegy (fluticasone furoate, umeclidinium, vilanterol) is indicated for the prevention of acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
Key Components
- Fluticasone furoate: an inhaled corticosteroid
- Umeclidinium: a long-acting muscarinic antagonist
- Vilanterol: a long-acting β-agonist
Evidence
The combination of vilanterol and umeclidinium was recently approved by the Food and Drug Administration for COPD as once-daily combination bronchodilator therapy 1. Additionally, the combination of fluticasone furoate and vilanterol has been shown to improve lung function and reduce exacerbations more effectively than either of its monocomponents 1. A study published in the Lancet Respir Med in 2013 also supports the use of once-daily inhaled fluticasone furoate and vilanterol for prevention of exacerbations of COPD 1.
Clinical Use
Trelegy is used as a once-daily inhalation therapy for patients with COPD to help prevent exacerbations and improve lung function.
From the Research
Indication for Trelegy (fluticasone furoate, umeclidinium, vilanterol)
- Trelegy is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2 agonist (LABA) 2
- It is used as a single-inhaler triple therapy for patients with COPD who remain symptomatic and/or have frequent exacerbations despite dual therapies 3, 4
- The treatment is intended to improve pulmonary function, symptoms, quality of life, and reduce the rate of moderate-severe exacerbations in patients with COPD 3, 5
Patient Population
- Trelegy is intended for adults with moderate to severe COPD who require maintenance treatment 2
- Patients should have a history of symptoms and/or frequent exacerbations despite treatment with dual therapies 3, 4
Clinical Evidence
- The IMPACT study demonstrated that triple therapy with Trelegy had a greater effect compared to dual therapies in reducing the rate of moderate-severe exacerbations, improving trough FEV1, and improving quality of life 3, 5
- A network meta-analysis found that Trelegy was statistically significantly more effective at increasing trough FEV1 and reducing the annualized rate of combined moderate or severe exacerbations compared to other triple therapy comparators 6